Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc.

Overview

• Delaware corporation; clinical-stage biopharmaceutical company.
• Focused on completing a proposed merger with Scancell Holdings plc while preserving cash and IP/value in partnered programs.
• Internal R&D is limited to the alpha7 nicotinic acetylcholine receptor (nAChR) negative allosteric modulator (NAM) portfolio. Lead asset: BNC210 (oral alpha7 NAM).

Recent corporate events and strategic posture

• Phase 3 AFFIRM-1 for BNC210 in social anxiety disorder (SAD) did not meet its primary endpoint; SAD program discontinued and AFFIRM-2 was not initiated.
• PTSD program for BNC210 is clinic-ready. The SYMPHONY Phase 2b/3 program is paused pending merger review with Scancell.
• Major fiscal 2026 restructuring: facility leases terminated; one full-time employee remains; operations conducted through consultants and external service providers (legal, accounting, interim CEO). Partner programs continue under their respective partners.
• Proposed merger with Scancell announced July 23, 2026. If completed, Neuphoria would become an indirect Scancell subsidiary and issue contingent value rights (CVRs) tied to specified post-closing proceeds (e.g., Merck and CTx CRC monetizations and a tax credit). Closing conditions include Scancell financing and a Neuphoria cash threshold.

Current portfolio and status

• BNC210 (alpha7 NAM)
  • PTSD: ATTUNE (Phase 2b) met its primary endpoint and showed improvements on MADRS and ISI. End-of-Phase 2 discussions with the FDA in mid-2024 contemplated a registrational trial plus a 52-week extension; no SYMPHONY trial was initiated and the program remains paused pending the merger.
  • SAD: PREVAIL (Phase 2) and AFFIRM-1 outcomes led to discontinuation of the SAD program.
  • Tablet reformulation was developed to address a food effect and was used in ATTUNE, PREVAIL, and AFFIRM-1.
  • FDA interactions occurred in 2024–2025 regarding a potential PTSD registrational path; there was no active start-up in 2026.
• Alpha7 PAM program (Merck)
  • MK-1167: Merck-led Phase 2 in Alzheimer's disease dementia was terminated after an interim analysis; Merck controls development and reporting.
  • MK-4334: Completed Phase 1 safety/biomarker studies; Merck controls ongoing development.
• Preclinical/legacy internal programs
  • In-house preclinical NAMs and Kv3.1/3.2 and Nav1.7/1.8 programs were cut back after restructuring; further advancement would require third-party licensing or collaboration.
• Partnered and legacy assets
  • BNC101 (LGR5-targeted CAR-T) licensed to Carina Biotech; Carina controls development. Neuphoria is eligible for milestones and royalties under the license.
  • Pfizer/CTx CRC KAT6 program: Neuphoria holds a passive economic interest (~4.65% of future distributions) via the former CTx CRC structure. A distribution of A$1.416 million was received on May 21, 2026; future distributions depend on program outcomes.
  • Ironwood license (BNC210): Neuphoria retains royalty potential in the low-to-mid single digits should commercialization occur. Rights previously reverted to Neuphoria following termination of the 2014 agreement.
  • BNC105 (oncology vascular-disrupting agent): not actively developed; potential value would be realized via third-party transactions.

Financial position (selected figures)

• Cash and cash equivalents: $19.9 million as of June 30, 2026.
• Accumulated deficit: approximately $191.8 million as of June 30, 2026.
• No product revenue to date; the company has recorded milestone and collaboration receipts.
• Recent non-operating receipts:
  • Merck milestone: $15.0 million received March 19, 2025 (for initiation of Merck Phase 2 of MK-1167).
  • CTx CRC distribution: A$1.416 million received May 21, 2026; Neuphoria expects ~4.65% of future distributions from the CTx CRC entities.
• CVR framework: post-closing potential cash flows to CVR holders depend on specified monetizations and tax credits; actual payments are contingent.
• Merger closing conditions include Scancell raising at least $75 million gross in concurrent financing and Neuphoria holding at least $10 million in cash at closing (or earlier).

Public status and governance

• Nasdaq-listed; compliance with listing requirements was regained on December 18, 2025. Continued compliance remains a factor for the company.
• Designated as an Emerging Growth Company under the JOBS Act and currently subject to related exemptions that may change over time.
• Ongoing exposure to going-concern considerations, need for additional financing, and dependence on third-party collaborations and strategic transactions.

Intellectual property

• CNS portfolio: multiple BNC210 patent families covering composition of matter, manufacturing, crystalline forms, salts/cocrystals/polymorphs, and solid-form formulations; patent expirations range from 2027 to 2040, subject to extensions and adjustments.
• Oncology portfolio: BNC101 IP includes multiple families with US and international patents; expirations range from 2033–2039.
• Carina/BNC101 license: Carina controls development; Neuphoria is eligible for up to A$118 million in milestones, low-to-mid single-digit royalties, and a share of sublicensing revenue.
• Merck collaboration: Merck controls development and commercialization timing; Neuphoria’s rights include potential milestone and royalty payments per amendment terms.
• Ironwood license: Neuphoria retains royalty potential on BNC210 if commercialized.

Key risks and considerations

• Dependence on third-party collaborators (Merck, Carina, Pfizer/CTx CRC) for development, regulatory, and commercialization activities.
• Uncertainty around completion of the Scancell merger and satisfaction of associated financing and cash thresholds; CVR outcomes depend on post-closing monetizations.
• Limited internal R&D following restructuring; substantial capital would be required to resume non-partnered development or to pursue new programs.
• Regulatory, manufacturing, and commercialization risks remain given no approved products to date.
• Market and financial risks include Nasdaq volatility, potential delisting, and the need for additional funding.

Business activities

• Discovery and development of CNS and oncology drug candidates, with historical emphasis on ion-channel biology and alpha7 receptor modulators.
• Development focus on BNC210 for PTSD (program clinic-ready but paused) and legacy involvement in SAD (program discontinued).
• Maintains partnered programs and economic interests with Merck, Pfizer/CTx CRC, Carina Biotech, and Ironwood.
• Pursuing strategic alternatives, including the proposed merger with Scancell and potential monetization of CVRs, while preserving IP and licensing arrangements.

Selected operational notes

• Employees: 1 full-time employee remaining; core activities supported by consultants and external service providers.
• Cash runway: $19.9 million as of June 30, 2026; going-concern considerations depend on the merger and additional financing.
• Major near-term event: Agreement and Plan of Merger with Scancell announced July 23, 2026; closing requires financing, stockholder approvals, and cash thresholds, and will issue CVRs to Neuphoria stockholders as part of the consideration.